AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Novel Coronavirus Treatment

997.990

+8.4130.85%

Number of Gainers:16

Number of Losers:2

Number of Flat:15

PE:- -

High:1,000.778

Open:987.709

Low:985.559

Close:989.577

Volume:28.32M

Turnover:220.99M

Market Cap:247.32B

Float Cap:202.77B

Loading ...

3 Australian Value Stocks For October 2026

Simply Wall St.

Australia's CSL Rises After Jefferies Sees Plasma Yield Upside

Terumo, CSL Plasma Mutually Terminate Supply Agreement; Terumo Expects $610 Million Loss

MT Newswires Live

Australia's CSL Set for Weekly Gain on Rare Diseases Drug Deal

Lark Distilling Co Ltd-Non-Executive Director Appointment

THOMSON REUTERS

CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform

MT Newswires Live

Carlisle Companies (CSL) Could Be 22% Undervalued Following Its Recent Pullback

Simply Wall St.

Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027

Haemonetics Says CSL Plasma Expects U.S. Rollout of Its Devices at All Centers by End-2027

Enters Agreement with Terumo Bct to Support Platform Transition

THOMSON REUTERS

Transition to Haemonetics Platform to Increase Plasma Collection Network Efficiency

THOMSON REUTERS

To Complete Haemonetics Platform Rollout in U.S. Plasma Centres by End 2027

THOMSON REUTERS

Expands Relationship with Haemonetics Corporation

THOMSON REUTERS

Genetic Signatures Reports Decline in Fiscal Q1 Sales

MT Newswires Live

Australia's Advance ZincTek Hits 8-Year Low on Weaker Sunscreen Orders

Noxopharm Says US FDA Feedback Supports Planned Phase II Trial Approach for Autoimmune Drug Candidate

MT Newswires Live

ASX Midday Sector Update: Consumer Staples Stocks Rise, Materials Sector Struggles

MT Newswires Live

Genetic Signatures - Q1 Fy2027 Sales A$4.0 Mln

THOMSON REUTERS

Cynata Therapeutics Terminates of At-the-Market Subscription Deed

Cynata Therapeutics Ltd - Termination of At

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hkg.itiger.com/stock/BK7501/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"Novel Coronavirus Treatment","latestPrice":997.99,"timestamp":1791521999484,"preClose":989.5767,"halted":0,"volume":28320907,"delay":0,"changeRate":0.008502,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":8.413269,"latestTime":"10-09 16:00:00 AEDT","open":987.7088,"high":1000.77844,"low":985.55884,"amount":220988344,"amplitude":0.01538,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791759600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1791500400000,1791522000000]],"turnoverRate":0.001978,"increases":14,"decrements":3,"flats":15,"marketCap":247320388041,"floatMarketCap":202766755196.8047},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":1000.77844,"amplitude":0.01538,"preClose":989.5767,"low":985.55884,"latestPrice":997.99,"volume":28320907,"delay":0,"open":987.7088,"prevYearClose":900.1661,"prevWeekClose":966.403,"prevMonthClose":999.613,"prevQuarterClose":999.613,"fiveDayClose":966.403,"twentyDayClose":945.016,"sixtyDayClose":834.051,"secType":"PLATE","market":"AU","turnoverRate":0.001978,"marketCap":247320388041,"floatMarketCap":202766755196.8047,"timestamp":1791521999484,"nameCN":"Novel Coronavirus Treatment"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":16,"down":2,"flat":15},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674851903","title":"3 Australian Value Stocks For October 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851903","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674851903?lang=en_us&edition=fundamental","pubTime":"2026-10-09 17:39","pubTimestamp":1791538780,"startTime":"0","endTime":"0","summary":"High oil prices and rising US Treasury yields are pushing many investors toward safer income options like government bonds. That can leave some Australian cash rich businesses trading on the back foot, even when their future cash flows look solid based on discounted cash flow work. This disconnect can create mispricing. In this article you will see three stocks that currently screen as interesting value opportunities on cash flows.\nThe three stocks in this article are just a sample set from...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2053000-choice1-card/1788945647432","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2053000-choice1-card/1788945647432"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ggp/greatland-resources-shares/news/3-australian-value-stocks-for-october-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ggp/greatland-resources-shares/news/3-australian-value-stocks-for-october-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QRE.AU","SPHQ","OZR.AU","EIGA.AU","E200.AU","BK7501","ZYAU.AU","QFN.AU","DACE.AU","ANN.AU","BBOZ.AU","BK7126","OZF.AU","BK7104","BK4588","VAS.AU","BK7142","GIVE.AU","IISV.AU","IMLC.AU","STW.AU","WDS.AU","IOZ.AU","IIGF.AU","XJO.AU","BK4585","GEAR.AU","SLF.AU","XAO.AU","BEAR.AU","GGP.AU","XKO.AU","VAP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674688773","title":"Australia's CSL Rises After Jefferies Sees Plasma Yield Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2674688773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674688773?lang=en_us&edition=fundamental","pubTime":"2026-10-09 11:31","pubTimestamp":1791516691,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL rises after Jefferies sees plasma yield upside** Shares of Australia's CSLCSL.AXrise as much as 1.62% to A$184.4** Jefferies says the biotechnology giant remains rated \"hold\", after its US plasma platform shift may lift efficiency but risks collection disruption** Brokerage says CSL will replace Terumo systems with Haemonetics equipment across about 330 US centres by the end of 2027** Jefferies notes channel checks suggest the new platform can deliver up to a 15% improvement in plasma collection yield** Adds a single newer platform is aligned with CSL's cost-per-litre and gross margin goals, though benefits are likely to emerge gradually** Jefferies says \"the key risks are collection disruption during the changeover\" and is watching for any disclosure of costs, savings and impairment** Stock for the week up 5.1% and putting the stock on track for its best week in a month","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nL6N45V057:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","CSL.AU","LU0205193047.USD","IE0034390439.USD","IE00B64QTZ34.USD","LU0106261612.USD","BK7501","HAE","LU1169589451.USD","BK7508","IE00B19Z6F94.USD","IE00BLDYK493.USD","LU0205194284.USD","LU0012050646.USD","BK7511","BK7067","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674827878","title":"Terumo, CSL Plasma Mutually Terminate Supply Agreement; Terumo Expects $610 Million Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2674827878","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674827878?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:46","pubTimestamp":1791513965,"startTime":"0","endTime":"0","summary":"Terumo  has mutually agreed with CSL Plasma to end their supply agreement for source plasma collection devices, and expects a loss of $610 million, according to a Thursday Tokyo bourse filing.The loss comprises $450 million in non-cash impairment losses and $160 million in transition, termination, and restructuring costs.Subsequently, Terumo revised its full-year guidance for the fiscal year ending March 31, 2027, cutting profit attributable to owners of the parent to 120 billion yen from 193.1 billion yen initially.Basic earnings per share estimates dropped to 81.35 yen from 130.91 yen, while revenue targets were cut to 1.23 trillion yen from 1.239 trillion yen.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","YCS","BK7501","FXY","BK7067","YCL","HEWJ","BK7511","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674788109","title":"Australia's CSL Set for Weekly Gain on Rare Diseases Drug Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2674788109","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674788109?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:27","pubTimestamp":1791509229,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL set for weekly gain on rare diseases drug deal** Shares of biotech firm CSLCSL.AXup over 4.8% so far this week, on track for best week since mid-September** On Monday, CSL said it","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nL4N45V01I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CSL.AU","BK7501","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674883301","title":"Lark Distilling Co Ltd-Non-Executive Director Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2674883301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674883301?lang=en_us&edition=fundamental","pubTime":"2026-10-09 05:41","pubTimestamp":1791495707,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUE2CVZJV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","LRK.AU","BK7097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674880588","title":"CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2674880588","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674880588?lang=en_us&edition=fundamental","pubTime":"2026-10-09 05:26","pubTimestamp":1791494795,"startTime":"0","endTime":"0","summary":"CSL  said it will transition its US plasma collection centers to Haemonetics' latest-generation plasmapheresis platform, with the rollout expected to be completed by the end of 2027, according to an Australian bourse filing on Thursday after market hours.The company has also reached an agreement with Terumo BCT, the provider of its current Rika system, to ensure a smooth transition, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CSL.AU","LU0205193047.USD","IE00B19Z6F94.USD","LU1169590202.USD","BK7067","BK7501","BK4198","IE00BLDYK493.USD","BK7508","LU1169589451.USD","IE00B64QTZ34.USD","BK7511","LU0012050646.USD","LU0205194284.USD","LU0106261612.USD","IE0034390439.USD","HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674007641","title":"Carlisle Companies (CSL) Could Be 22% Undervalued Following Its Recent Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2674007641","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674007641?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:29","pubTimestamp":1791487783,"startTime":"0","endTime":"0","summary":"Carlisle Companies (CSL) has come back into focus after a recent share price slide, with the stock down about 10% over the past month and roughly 4% over the past year.\nThe recent slide comes after a softer few months for Carlisle Companies, with the share price down over the past quarter and its 1-year total shareholder return slightly negative despite strong multi year gains. That pattern suggests momentum has cooled as investors reassess growth prospects and risk, rather than responding to...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3031000-choice1-card/1788980882312","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3031000-choice1-card/1788980882312"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-csl-could-be-22-undervalued-following-its","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-csl-could-be-22-undervalued-following-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL","BK7501","LU1169590202.USD","SG9999004303.SGD","BK7508","BK7067","CSL.AU","LU1169589451.USD","BK4086","SGXZ23171101.USD","LU0728928796.USD","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673907746","title":"Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673907746","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673907746?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:50","pubTimestamp":1791463800,"startTime":"0","endTime":"0","summary":"Shares of Haemonetics rose after CSL Plasma said it expects to complete the rollout of the company's devices and disposables under their supply agreement by the end of 2027.The stock gained 16% to $118 in premarket trading Thursday. At Wednesday's market close, shares were up 27% year to date.Under the supply agreement, which the companies entered in August, CSL can use Haemonetics' NexSys PCS devices and purchase related disposables in the U.S. Haemonetics said at the time the supply agreement was non-exclusive and did not contain minimum purchase commitments.In a Thursday filing with the Securities and Exchange Commission, Haemonetics said CSL expects the transition to its devices and disposables will occur at all of CSL's current U.S. plasma collection centers.The scope and timing of the rollout remain subject to change, Haemonetics said, noting it is not updating its previously issued fiscal 2027 guidance at this time.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261612.USD","IE00BLDYK493.USD","HAE","IE0034390439.USD","IE00B19Z6F94.USD","LU0012050646.USD","BK4198","LU0205194284.USD","BK7511","LU1169590202.USD","BK7067","LU0205193047.USD","IE00B64QTZ34.USD","CSL.AU","BK7501","LU1169589451.USD","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673075157","title":"Haemonetics Says CSL Plasma Expects U.S. Rollout of Its Devices at All Centers by End-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673075157","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673075157?lang=en_us&edition=fundamental","pubTime":"2026-10-08 18:16","pubTimestamp":1791454562,"startTime":"0","endTime":"0","summary":"Haemonetics says CSL Plasma expects U.S. rollout of its devices at all centers by end-2027Haemonetics disclosed an update on its non-exclusive U.S. supply agreement with CSL Plasma for NexSys PCS devi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL2PrFZb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","IE00BLDYK493.USD","LU0012050646.USD","BK7511","BK7508","IE0034390439.USD","LU1169589451.USD","LU1169590202.USD","LU0205193047.USD","BK7067","IE00B64QTZ34.USD","LU0106261612.USD","LU0205194284.USD","IE00B19Z6F94.USD","CSL.AU","BK7501","HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673402107","title":"Enters Agreement with Terumo Bct to Support Platform Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2673402107","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673402107?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:45","pubTimestamp":1791445508,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T253:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CSL.AU","BK7067","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673210760","title":"Transition to Haemonetics Platform to Increase Plasma Collection Network Efficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2673210760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673210760?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:45","pubTimestamp":1791445508,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T253:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CSL.AU","BK7067","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673071021","title":"To Complete Haemonetics Platform Rollout in U.S. Plasma Centres by End 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673071021","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673071021?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:45","pubTimestamp":1791445508,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T253:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","CSL.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673021079","title":"Expands Relationship with Haemonetics Corporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2673021079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673021079?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:45","pubTimestamp":1791445508,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T253:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CSL.AU","BK7511","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673404560","title":"Genetic Signatures Reports Decline in Fiscal Q1 Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2673404560","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673404560?lang=en_us&edition=fundamental","pubTime":"2026-10-08 12:27","pubTimestamp":1791433628,"startTime":"0","endTime":"0","summary":"Genetic Signatures (ASX:GSS) reported fiscal first-quarter sales of AU$4 million, down from AU$5.4 million a year earlier, according to a Thursday filing with the Australian bourse.Working under a res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GSS.AU","BK7501","BK7048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673047545","title":"Australia's Advance ZincTek Hits 8-Year Low on Weaker Sunscreen Orders","url":"https://stock-news.laohu8.com/highlight/detail?id=2673047545","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673047545?lang=en_us&edition=fundamental","pubTime":"2026-10-08 11:29","pubTimestamp":1791430166,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Advance ZincTek hits 8-year low on weaker sunscreen orders** Shares of Australia's Advance ZincTekANO.AXtumble 4% to an eight-year low of A$0.60 at open, stay pinned at that level** C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nL4N45U07J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANO.AU","BK7501","BK7036"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673044724","title":"Noxopharm Says US FDA Feedback Supports Planned Phase II Trial Approach for Autoimmune Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2673044724","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673044724?lang=en_us&edition=fundamental","pubTime":"2026-10-08 10:24","pubTimestamp":1791426258,"startTime":"0","endTime":"0","summary":"Noxopharm   said the US Food and Drug Administration has provided constructive feedback that was supportive of its planned approach for a phase II clinical trial for SOF-SKN, its autoimmune disease drug candidate, according to a Thursday Australian bourse filing.The company said the feedback provides increased regulatory clarity, and helps de-risk the drug candidate's development pathway, while it will incorporate the feedback into preparations for a future investigational new drug  submission that has the potential to increase SOF-SKN's commercial attractiveness.The phase II trial is targeted for the first half of calendar 2028, subject to regulatory, clinical and manufacturing requirements, it said.The company said an orphan drug designation opportunity exists for SOF-SKN, given there are no current targeted therapies.The company's shares fell nearly 2% in recent Thursday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","IND","BK7095","BK7508","BK4588","IND.AU","NOX.AU","BK7501","BK7067","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673041221","title":"ASX Midday Sector Update: Consumer Staples Stocks Rise, Materials Sector Struggles","url":"https://stock-news.laohu8.com/highlight/detail?id=2673041221","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673041221?lang=en_us&edition=fundamental","pubTime":"2026-10-08 09:41","pubTimestamp":1791423693,"startTime":"0","endTime":"0","summary":"Consumer staples stocks advanced more than 1% at midday Thursday.Woolworths Group (ASX:WOW) gained more than 1% in recent trade.On the flip side, the materials sector struggled, shedding over 2%.BHP Group (ASX:BHP) shares fell past 2% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","UYM","BK7511","WOW.AU","BHP.AU","BK7095","BK7507","BK7040"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673041469","title":"Genetic Signatures - Q1 Fy2027 Sales A$4.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2673041469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673041469?lang=en_us&edition=fundamental","pubTime":"2026-10-08 09:37","pubTimestamp":1791423463,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T28T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GSS.AU","BK7048","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673049962","title":"Cynata Therapeutics Terminates of At-the-Market Subscription Deed","url":"https://stock-news.laohu8.com/highlight/detail?id=2673049962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673049962?lang=en_us&edition=fundamental","pubTime":"2026-10-08 08:51","pubTimestamp":1791420662,"startTime":"0","endTime":"0","summary":"BRIEF-Cynata Therapeutics Terminates Of At-The-Market Subscription DeedOct 8 (Reuters)-Cynata Therapeutics LtdCYP.AX:TERMINATION OF AT--MARKET SUBSCRIPTION DEEDFurther company coverage:CYP.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45T23M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7508","CYP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673304353","title":"Cynata Therapeutics Ltd - Termination of At","url":"https://stock-news.laohu8.com/highlight/detail?id=2673304353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673304353?lang=en_us&edition=fundamental","pubTime":"2026-10-08 05:27","pubTimestamp":1791408469,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T23M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYP.AU","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":90,"code":"91000000","status":"200"}]}}